The webinar will feature a presentation from Key Opinion Leader (KOL) Charles Brenner, PhD (City of Hope National Medical Center) who will discuss the latest research on Nicotinamide Riboside (NR) and its many benefits as a precursor to Nicotinamide Adenine Dinucleotide (NAD). NAD is the central catalyst to multiple metabolic processes and a critical ally to resilience and repair in healthy aging.

ChromaDex’s TruNiagen® will be discussed as the market’s most scientifically-supported way to boost NAD. Rob Fried, ChromaDex’s President & CEO, will provide a company update.

A live question and answer session will follow.